LogicBio Therapeutics (OTCMKTS:LOGC) Announces Earnings Results

LogicBio Therapeutics (OTCMKTS:LOGC) posted its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10), Zacks reports.

LogicBio Therapeutics Price Performance

Shares of LOGC stock remained flat at $10.50 during trading hours on Thursday. 127,031 shares of the stock traded hands, compared to its average volume of 139,952. LogicBio Therapeutics has a 52-week low of $7.05 and a 52-week high of $10.61. The business’s fifty day moving average is $9.36 and its two-hundred day moving average is $8.66. The firm has a market capitalization of $480.17 million, a PE ratio of -9.63 and a beta of 2.02. The company has a quick ratio of 1.15, a current ratio of 1.67 and a debt-to-equity ratio of 0.28.

Institutional Trading of LogicBio Therapeutics

An institutional investor recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. lifted its stake in LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) by 284.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 526,673 shares of the company’s stock after purchasing an additional 389,843 shares during the period. Goldman Sachs Group Inc. owned about 2.00% of LogicBio Therapeutics worth $3,676,000 at the end of the most recent quarter. 46.05% of the stock is owned by institutional investors.

About LogicBio Therapeutics

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.